Shawn Cross, the Chief Financial Officer of $PCRX, sold 15,896 shares of the company on 12-09-2025 for an estimated $397,876. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.0% of their shares of this class of stock. Following this trade, they now own 56,250 shares of this class of $PCRX stock.
$PCRX Insider Trading Activity
$PCRX insiders have traded $PCRX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 3 sales selling 37,060 shares for an estimated $893,156.
- MARCELO BIGAL sold 4,912 shares for an estimated $116,267
- JONATHAN SLONIN (Chief Medical Officer) sold 3,960 shares for an estimated $95,396
- ABRAHAM CEESAY sold 2,354 shares for an estimated $64,005
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCRX Hedge Fund Activity
We have seen 106 institutional investors add shares of $PCRX stock to their portfolio, and 149 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POLAR CAPITAL HOLDINGS PLC removed 910,455 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,462,425
- DOMA PERPETUAL CAPITAL MANAGEMENT LLC added 897,255 shares (+49.7%) to their portfolio in Q3 2025, for an estimated $23,122,261
- BLACKROCK, INC. removed 459,831 shares (-5.9%) from their portfolio in Q3 2025, for an estimated $11,849,844
- ECOR1 CAPITAL, LLC removed 457,471 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,789,027
- MILLENNIUM MANAGEMENT LLC removed 444,266 shares (-86.3%) from their portfolio in Q3 2025, for an estimated $11,448,734
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 409,997 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,565,622
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 332,162 shares (-33.7%) from their portfolio in Q3 2025, for an estimated $8,559,814
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PCRX Revenue
$PCRX had revenues of $179.5M in Q3 2025. This is an increase of 6.49% from the same period in the prior year.
You can track PCRX financials on Quiver Quantitative's PCRX stock page.
$PCRX Analyst Ratings
Wall Street analysts have issued reports on $PCRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/17/2025
- Truist Securities issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for $PCRX, check out Quiver Quantitative's $PCRX forecast page.
$PCRX Price Targets
Multiple analysts have issued price targets for $PCRX recently. We have seen 3 analysts offer price targets for $PCRX in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $27.0 on 12/09/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $38.0 on 11/17/2025
- Les Sulewski from Truist Securities set a target price of $28.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
